Company Overview of Hemobiotech, Inc.
Hemobiotech, Inc., a biopharmaceutical company, provides research and development of human blood substitute technology licensed from Texas Tech University Health Service Center in Texas. It focuses primarily on the development of HemoTech, an oxygen-carrying solution that performs like red blood cells. The company was incorporated in 2003 and is headquartered in Dallas, Texas.
5001 Spring Valley Road
Suite 1040 - West
Dallas, TX 75244
Founded in 2003
Key Executives for Hemobiotech, Inc.
Interim Chief Executive Officer, Director, Chairman of Audit Committee and Member of Nominating & Corporate Governance Committee
Founder and Vice Chairman
Interim Chief Financial Officer, Secretary, Director, Member of Nominating & Corporate Governance Committee and Member of Compensation Committee
Acting Vice President, Principal Investigator of Research & Development and Advisor
Compensation as of Fiscal Year 2015.
Hemobiotech, Inc. Key Developments
SEC Revokes Registration Of Registered Securities Of HemoBioTech
Oct 23 13
An Administrative Law Judge has issued an initial decision of default as to HemoBioTech, Inc. The Order Instituting Proceedings alleged that the company repeatedly failed to file timely periodic reports while its securities were registered with the Securities and Exchange Commission (SEC or the Commission). SEC finds these allegations to be true as to company and revokes the registration of each class of their registered securities, pursuant to Section 12(j) of the Securities Exchange Act of 1934.
SEC Orders Hearing On Registration Suspension Or Revocation Against HemoBioTech
Sep 18 13
In conjunction with trading suspension, the Securities and Exchange Commission (SEC) also instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of HemoBioTech, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company is delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries